{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:15Z","timestamp":1787020215705,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Harbin Medical University Graduate Student Research and Practice Innovation Project","award":["YJSCX2024-111HYD"],"award-info":[{"award-number":["YJSCX2024-111HYD"]}]},{"name":"Harbin Medical University Graduate Student Research and Practice Innovation Project","award":["YJSCX2024-111HYD"],"award-info":[{"award-number":["YJSCX2024-111HYD"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52272273"],"award-info":[{"award-number":["52272273"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific research project of China Medical Education Association","award":["2022KTM025"],"award-info":[{"award-number":["2022KTM025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13354-8","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T04:08:54Z","timestamp":1734667734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Establishment and clinical application of a prognostic index for inflammatory status in triple-negative breast cancer patients undergoing neoadjuvant therapy using machine learning"],"prefix":"10.1186","volume":"24","author":[{"given":"Hao","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanglong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingna","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiyasi","family":"Nanding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"13354_CR1","doi-asserted-by":"publisher","first-page":"106535","DOI":"10.1016\/j.intimp.2020.106535","volume":"84","author":"K Barzaman","year":"2020","unstructured":"Barzaman K, Karami J, Zarei Z, et al. Breast cancer: Biology, biomarkers, and treatments. INT IMMUNOPHARMACOL. 2020;84:106535. https:\/\/doi.org\/10.1016\/j.intimp.2020.106535.","journal-title":"INT IMMUNOPHARMACOL"},{"key":"13354_CR2","doi-asserted-by":"publisher","unstructured":"Kawiak A. Molecular Research and treatment of breast Cancer. Int J Mol Sci. 2022;23(17). https:\/\/doi.org\/10.3390\/ijms23179617.","DOI":"10.3390\/ijms23179617"},{"key":"13354_CR3","doi-asserted-by":"publisher","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast Cancer Treatment options and limitations: Future Outlook. Pharmaceutics. 2023;15(7). https:\/\/doi.org\/10.3390\/pharmaceutics15071796.","DOI":"10.3390\/pharmaceutics15071796"},{"issue":"1","key":"13354_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022;8(1):95. https:\/\/doi.org\/10.1038\/s41523-022-00468-0.","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"13354_CR5","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/bjc.2016.283","volume":"115","author":"G Houvenaeghel","year":"2016","unstructured":"Houvenaeghel G, Sabatier R, Reyal F, et al. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. BRIT J CANCER. 2016;115(9):1024\u201331. https:\/\/doi.org\/10.1038\/bjc.2016.283.","journal-title":"BRIT J CANCER"},{"issue":"2","key":"13354_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","volume":"161","author":"X Li","year":"2016","unstructured":"Li X, Yang J, Peng L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. BREAST CANCER RES TR. 2016;161(2):279\u201387. https:\/\/doi.org\/10.1007\/s10549-016-4059-6.","journal-title":"BREAST CANCER RES TR"},{"issue":"8","key":"13354_CR7","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J CLIN ONCOL. 2008;26(8):1275\u201381. https:\/\/doi.org\/10.1200\/JCO.2007.14.4147.","journal-title":"J CLIN ONCOL"},{"issue":"13","key":"13354_CR8","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast Cancer: ASCO Guideline. J CLIN ONCOL. 2021;39(13):1485\u2013505. https:\/\/doi.org\/10.1200\/JCO.20.03399.","journal-title":"J CLIN ONCOL"},{"issue":"7","key":"13354_CR9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","volume":"29","author":"F Poggio","year":"2018","unstructured":"Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. ANN ONCOL. 2018;29(7):1497\u2013508. https:\/\/doi.org\/10.1093\/annonc\/mdy127.","journal-title":"ANN ONCOL"},{"key":"13354_CR10","doi-asserted-by":"publisher","unstructured":"van den Ende NS, Nguyen AH, Jager A, et al. Triple-negative breast Cancer and predictive markers of response to Neoadjuvant Chemotherapy: a systematic review. Int J Mol Sci. 2023;24(3). https:\/\/doi.org\/10.3390\/ijms24032969.","DOI":"10.3390\/ijms24032969"},{"issue":"6","key":"13354_CR11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s12282-023-01504-y","volume":"30","author":"H Kusama","year":"2023","unstructured":"Kusama H, Kittaka N, Soma A, et al. Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer. BREAST CANCER-TOKYO. 2023;30(6):1085\u201393. https:\/\/doi.org\/10.1007\/s12282-023-01504-y.","journal-title":"BREAST CANCER-TOKYO"},{"issue":"1","key":"13354_CR12","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1186\/s12885-023-11435-8","volume":"23","author":"J Gu","year":"2023","unstructured":"Gu J, Deng S, Jiang Z, et al. Modified Naples prognostic score for evaluating the prognosis of patients with obstructive colorectal cancer. BMC Cancer. 2023;23(1):941. https:\/\/doi.org\/10.1186\/s12885-023-11435-8.","journal-title":"BMC Cancer"},{"issue":"11","key":"13354_CR13","first-page":"5743","volume":"11","author":"Y Tokumaru","year":"2021","unstructured":"Tokumaru Y, Oshi M, Murthy V, et al. Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC). Am J Cancer Res. 2021;11(11):5743\u201355. PMID: 34873491.","journal-title":"Am J Cancer Res"},{"key":"13354_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3389\/fimmu.2019.00757","volume":"10","author":"Y Liubomirski","year":"2019","unstructured":"Liubomirski Y, Lerrer S, Meshel T, et al. Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in Triple-negative breast Cancer. Front Immunol. 2019;10:757. https:\/\/doi.org\/10.3389\/fimmu.2019.00757.","journal-title":"Front Immunol"},{"key":"13354_CR15","doi-asserted-by":"publisher","first-page":"112332","DOI":"10.1016\/j.intimp.2024.112332","volume":"136","author":"H Xie","year":"2024","unstructured":"Xie H, Ruan G, Wei L, et al. Obesity-associated metabolic inflammation promotes triple-negative breast cancer progression through the interleukin-6\/STAT3\/pentraxin 3\/matrix metalloproteinase 7 axis. INT IMMUNOPHARMACOL. 2024;136:112332. https:\/\/doi.org\/10.1016\/j.intimp.2024.112332.","journal-title":"INT IMMUNOPHARMACOL"},{"issue":"8","key":"13354_CR16","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/jnci\/djae056","volume":"116","author":"N Kumar","year":"2024","unstructured":"Kumar N, Ehsan S, Banerjee S, et al. The unique risk factor profile of triple-negative breast cancer: a comprehensive meta-analysis. JNCI-J NATL CANCER I. 2024;116(8):1210\u20139. https:\/\/doi.org\/10.1093\/jnci\/djae056.","journal-title":"JNCI-J NATL CANCER I"},{"key":"13354_CR17","doi-asserted-by":"publisher","unstructured":"Cocco S, Piezzo M, Calabrese A, et al. Biomarkers in Triple-negative breast Cancer: state-of-the-art and future perspectives. Int J Mol Sci. 2020;21(13). https:\/\/doi.org\/10.3390\/ijms21134579.","DOI":"10.3390\/ijms21134579"},{"issue":"1","key":"13354_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74. https:\/\/doi.org\/10.1186\/s40425-018-0383-1.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"13354_CR19","doi-asserted-by":"publisher","first-page":"886","DOI":"10.21037\/tlcr.2019.11.16","volume":"8","author":"H Mandaliya","year":"2019","unstructured":"Mandaliya H, Jones M, Oldmeadow C, et al. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). TRANSL LUNG CANCER R. 2019;8(6):886\u201394. https:\/\/doi.org\/10.21037\/tlcr.2019.11.16.","journal-title":"TRANSL LUNG CANCER R"},{"key":"13354_CR20","doi-asserted-by":"publisher","first-page":"1142168","DOI":"10.3389\/fonc.2023.1142168","volume":"13","author":"G Wenpei","year":"2023","unstructured":"Wenpei G, Yuan L, Liangbo L, et al. Predictive value of preoperative inflammatory indexes for postoperative early recurrence of hepatitis B-related hepatocellular carcinoma. Front Oncol. 2023;13:1142168. https:\/\/doi.org\/10.3389\/fonc.2023.1142168.","journal-title":"Front Oncol"},{"issue":"8","key":"13354_CR21","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1007\/s10238-023-01230-x","volume":"23","author":"S Nakamoto","year":"2023","unstructured":"Nakamoto S, Shien T, Itoh M, et al. Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study. CLIN EXP MED. 2023;23(8):5129\u201338. https:\/\/doi.org\/10.1007\/s10238-023-01230-x.","journal-title":"CLIN EXP MED"},{"key":"13354_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2147\/CMAR.S185890","volume":"11","author":"P Wang","year":"2019","unstructured":"Wang P, Yue W, Li W, et al. Systemic immune-inflammation index and ultrasonographic classification of breast imaging-reporting and data system predict outcomes of triple-negative breast cancer. Cancer Manag Res. 2019;11:813\u20139. https:\/\/doi.org\/10.2147\/CMAR.S185890.","journal-title":"Cancer Manag Res"},{"issue":"28","key":"13354_CR23","doi-asserted-by":"publisher","first-page":"e29887","DOI":"10.1097\/MD.0000000000029887","volume":"101","author":"Y Liu","year":"2022","unstructured":"Liu Y, He M, Wang C, et al. Prognostic value of neutrophil-to-lymphocyte ratio for patients with triple-negative breast cancer: a meta-analysis. Medicine. 2022;101(28):e29887. https:\/\/doi.org\/10.1097\/MD.0000000000029887.","journal-title":"Medicine"},{"key":"13354_CR24","doi-asserted-by":"publisher","first-page":"678315","DOI":"10.3389\/fonc.2021.678315","volume":"11","author":"S Lusho","year":"2021","unstructured":"Lusho S, Durando X, Mouret-Reynier MA, et al. Platelet-to-lymphocyte ratio is Associated with favorable response to Neoadjuvant Chemotherapy in Triple negative breast Cancer: a study on 120 patients. Front Oncol. 2021;11:678315. https:\/\/doi.org\/10.3389\/fonc.2021.678315.","journal-title":"Front Oncol"},{"key":"13354_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12885-015-1204-2","volume":"15","author":"M Pistelli","year":"2015","unstructured":"Pistelli M, De Lisa M, Ballatore Z, et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer. 2015;15:195. https:\/\/doi.org\/10.1186\/s12885-015-1204-2.","journal-title":"BMC Cancer"},{"issue":"1","key":"13354_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s43018-022-00480-0","volume":"4","author":"A Lasry","year":"2022","unstructured":"Lasry A, Nadorp B, Fornerod M, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2022;4(1):27\u201342. https:\/\/doi.org\/10.1038\/s43018-022-00480-0.","journal-title":"Nat Cancer"},{"issue":"8","key":"13354_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2217\/fon-2019-0732","volume":"16","author":"J Lei","year":"2020","unstructured":"Lei J, Wang Y, Guo X, et al. Low preoperative serum ALB level is independently associated with poor overall survival in endometrial cancer patients. FUTURE ONCOL. 2020;16(8):307\u201316. https:\/\/doi.org\/10.2217\/fon-2019-0732.","journal-title":"FUTURE ONCOL"},{"key":"13354_CR28","doi-asserted-by":"publisher","first-page":"924210","DOI":"10.3389\/fonc.2022.924210","volume":"12","author":"J Zhu","year":"2022","unstructured":"Zhu J, Li L, Duan Y, et al. Prognostic role of pre-treatment serum ALB in patients with oropharyngeal cancer: a retrospective cohort study. Front Oncol. 2022;12:924210. https:\/\/doi.org\/10.3389\/fonc.2022.924210.","journal-title":"Front Oncol"},{"issue":"5","key":"13354_CR29","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1002\/jcsm.13555","volume":"15","author":"H Xie","year":"2024","unstructured":"Xie H, Wei L, Ruan G, et al. AWGC2023 cachexia consensus as a valuable tool for predicting prognosis and burden in Chinese patients with cancer. J CACHEXIA SARCOPENI. 2024;15(5):2084\u201393. https:\/\/doi.org\/10.1002\/jcsm.13555.","journal-title":"J CACHEXIA SARCOPENI"},{"issue":"1","key":"13354_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/jcsm.12906","volume":"13","author":"A Takagi","year":"2021","unstructured":"Takagi A, Hawke P, Tokuda S, et al. Serum carnitine as a biomarker of Sarcopenia and nutritional status in preoperative gastrointestinal cancer patients. J CACHEXIA SARCOPENI. 2021;13(1):287\u201395. https:\/\/doi.org\/10.1002\/jcsm.12906.","journal-title":"J CACHEXIA SARCOPENI"},{"key":"13354_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.clnesp.2020.05.007","volume":"38","author":"E Rinninella","year":"2020","unstructured":"Rinninella E, Cintoni M, Raoul P, et al. Effects of nutritional interventions on nutritional status in patients with gastric cancer: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2020;38:28\u201342. https:\/\/doi.org\/10.1016\/j.clnesp.2020.05.007.","journal-title":"Clin Nutr ESPEN"},{"issue":"1","key":"13354_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.clnu.2023.11.030","volume":"43","author":"N Chen","year":"2023","unstructured":"Chen N, Yu Y, Shen W, et al. Nutritional status as prognostic factor of advanced oesophageal cancer patients treated with immune checkpoint inhibitors. CLIN NUTR. 2023;43(1):142\u201353. https:\/\/doi.org\/10.1016\/j.clnu.2023.11.030.","journal-title":"CLIN NUTR"},{"issue":"4","key":"13354_CR33","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/01635581.2023.2178938","volume":"75","author":"E Foecke Munden","year":"2023","unstructured":"Foecke Munden E, Kemp M, Guth A, et al. Patient-important needs and goals related to Nutrition interventions during Cancer Treatment. NUTR CANCER. 2023;75(4):1143\u201350. https:\/\/doi.org\/10.1080\/01635581.2023.2178938.","journal-title":"NUTR CANCER"},{"key":"13354_CR34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","volume":"111","author":"S Diem","year":"2017","unstructured":"Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176\u201381. https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.024.","journal-title":"Lung Cancer"},{"issue":"1","key":"13354_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12916-020-01817-1","volume":"18","author":"MA Cupp","year":"2020","unstructured":"Cupp MA, Cariolou M, Tzoulaki I, et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18(1):360. https:\/\/doi.org\/10.1186\/s12916-020-01817-1.","journal-title":"BMC Med"},{"issue":"3","key":"13354_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","volume":"22","author":"CC Hedrick","year":"2021","unstructured":"Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. NAT REV IMMUNOL. 2021;22(3):173\u201387. https:\/\/doi.org\/10.1038\/s41577-021-00571-6.","journal-title":"NAT REV IMMUNOL"},{"key":"13354_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","volume":"4","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59. https:\/\/doi.org\/10.1186\/s40425-016-0165-6.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"13354_CR38","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41416-020-01106-x","volume":"124","author":"SP Ng","year":"2020","unstructured":"Ng SP, Bahig H, Jethanandani A, et al. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. BRIT J CANCER. 2020;124(3):628\u201333. https:\/\/doi.org\/10.1038\/s41416-020-01106-x.","journal-title":"BRIT J CANCER"},{"issue":"11","key":"13354_CR39","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.hpb.2016.08.006","volume":"18","author":"EW Beal","year":"2016","unstructured":"Beal EW, Wei L, Ethun CG, et al. Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US extrahepatic biliary Malignancy Consortium. HPB. 2016;18(11):950\u20137. https:\/\/doi.org\/10.1016\/j.hpb.2016.08.006.","journal-title":"HPB"},{"issue":"1","key":"13354_CR40","doi-asserted-by":"publisher","first-page":"20980","DOI":"10.1038\/s41598-024-72027-5","volume":"14","author":"Y He","year":"2024","unstructured":"He Y, Liu X, Wang M, et al. Neutrophil-to-lymphocyte ratio as a predictor of cardiovascular mortality in cancer survivors. Sci Rep. 2024;14(1):20980. https:\/\/doi.org\/10.1038\/s41598-024-72027-5.","journal-title":"Sci Rep"},{"key":"13354_CR41","doi-asserted-by":"publisher","first-page":"1408700","DOI":"10.3389\/fimmu.2024.1408700","volume":"15","author":"S Tan","year":"2024","unstructured":"Tan S, Zheng Q, Zhang W, et al. Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review. Front Immunol. 2024;15:1408700. https:\/\/doi.org\/10.3389\/fimmu.2024.1408700.","journal-title":"Front Immunol"},{"issue":"6","key":"13354_CR42","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s11154-023-09845-x","volume":"24","author":"E Russo","year":"2023","unstructured":"Russo E, Guizzardi M, Canali L, et al. Preoperative systemic inflammatory markers as prognostic factors in differentiated thyroid cancer: a systematic review and meta-analysis. REV ENDOCR METAB DIS. 2023;24(6):1205\u201316. https:\/\/doi.org\/10.1007\/s11154-023-09845-x.","journal-title":"REV ENDOCR METAB DIS"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13354-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13354-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13354-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T05:03:15Z","timestamp":1734670995000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13354-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13354"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13354-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Helsinki Declaration and received approval from the ethics committee of Sixth Affiliated Hospital of Harbin Medical University (LC2024-052). All patients signed an \u201cInformed Consent Form for the Secondary Use of Medical History Data\/Biological Specimens\u201d. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1559"}}